#United States #Fort Worth #NanOlogy #David Arthur #LSAM

NanOlogy Appoints New CEO to Accelerate Drug Development

NanOlogy, LLC, a cutting-edge clinical-stage oncology company based in Fort Worth, Texas, recently announced the appointment of David J. Arthur as its new Chief Executive Officer. This strategic decision marks a significant milestone for the organization as it aims to expedite the clinical development of its Large Surface Area Microparticle (LSAM) investigational drug portfolio. This portfolio includes a promising treatment program targeting Diffuse Intrinsic Pontine Glioma (DIPG), a highly challenging form of pediatric brain cancer, which currently has limited treatment options available.

David Arthur's Expertise

Beginning his career over 35 years ago, David has garnered extensive experience within the pharmaceutical sector, focusing on product development, strategy, operations, and commercialization. His most recent role was as CEO of Salarius Pharmaceuticals, Inc., where he successfully transformed the company into a multiple-product clinical stage oncology firm and oversaw its public listing on NASDAQ. Prior to his tenure at Salarius, David held various executive positions at renowned companies such as Eli Lilly and Boehringer Ingelheim, further enriching his expertise in the industry.

Goals and Vision

In his new role at NanOlogy, David is expected to not only accelerate existing drug development activities but also enhance business development plans and the introduction of new drug programs. H. Paul Dorman, the founder and Chairman of NanOlogy, expressed confidence in David’s ability to strengthen the organization. He highlighted that the company had successfully completed clinical trials in six different solid tumors using LSAM investigational drugs and aims to find development partners to further advance these innovative therapies.

“To support our ongoing projects, we look forward to submitting an Investigational New Drug (IND) application to the FDA for a rare pediatric brainstem tumor treatment in mid-2026. With David's track record and capabilities, we believe he will play a crucial role in driving these initiatives forward, while also identifying strategic and financial partners to help us achieve our goals,” stated Dorman.

A Vision for Patients

David Arthur shared his enthusiasm for the advancements NanOlogy has made in drug development. He commented on the potential impact of intratumoral drugs and alternative administration methods, like inhalation, to significantly improve treatment outcomes compared to conventional systemic cancer therapies.

“My objective is to build on NanOlogy’s existing progress and develop a robust strategy that benefits not only cancer patients but also enhances shareholder value,” said Arthur.

About NanOlogy

Founded to pursue innovative cancer treatments, NanOlogy, LLC specializes in developing therapies for solid tumors utilizing drugs that are optimized for intratumoral delivery. By employing the Purcision™ technology platform developed by CritiTech Particle Engineering Solutions, the company creates Large Surface Area Microparticles (LSAMs) for local drug delivery, addressing challenges associated with systemic toxicity and ensuring better tumor bioavailability.

The company’s clinical projects have advanced LSAM investigational drugs aimed at treating various solid tumors including pancreatic, lung, bladder, peritoneal, ovarian, prostate, and dermal cancers. Moreover, the feasibility of the Purcision™ model has been validated for use with taxanes, platins, and other essential agents used in oncology treatment.

NanOlogy’s investigational drugs are supported by a vast intellectual property portfolio consisting of over 100 issued patents protecting their formulations and methodologies across critical global markets, including the United States, Europe, Japan, and India.

As NanOlogy moves forward under the guidance of David Arthur, the stage is set for impactful developments in the field of oncology, particularly aimed at treating pediatric cancers that desperately need innovative solutions.